摘要
回顾性调查沈阳市胸科医院2016年7月至2017年6月住院诊治的痰培养阳性且菌种鉴定为结核分枝杆菌的499例肺结核并发糖尿病患者的耐药检测结果，其中初治患者235例（初治组）、复治患者264例（复治组）。采用绝对浓度法测定结核分枝杆菌对11种抗结核药物的耐药性。结果显示，总耐药率为50．70％（253／499），初治组[29．79％（70／235）]低于复治组[69．32％（183／264）]（x2=79．32，P〈0．01）；单耐药率为14．83％（74／499），初、复治组[分别为14．04％（33／235）和15．53％（41／264）]差异无统计学意义（x2=0．22，P=0．641）；多耐药率为12．63％（63／499），初治组[2．98％（7／235）]低于复治组[21．21%（56／264）]（x2=37．47，P〈0．01）；耐多药率为23．25％（116／499），初治组[（12．77％（30／235）]低于复治组[32．58％（86／264）]（x2=27．35，P〈0．01）；广泛耐药率为3．01％（15／499），初治组[0．85％（2／235）]低于复治组[4．92％（13／264）]（x2=7．08，P=0．008）；利福平耐药率为29．26％（146／499），初治组[15．74％（37／235）]低于复治组[41．29％（109／264）]（x2=39．19，P〈0．01）。根据药物敏感性试验结果制定合理有效的耐药肺结核治疗方案，可为临床化疗方案的制定及耐药结核病的防治策略提供参考依据。
The drug susceptibility testing （DST） results and relevant information were collected from 499 patients who were diagnosed as sputum culture-positive pulmonary tuberculosis （TB）, identified as Mycobacterium tuberculosis （MTB） infection and combined with diabetes mellitus （DM）, were hospitalized at Shenyang Chest Hospital for treatment from July 2016 to June 2017. The DST results and the related information were retrospective analyzed. Among those enrolled patients, 235 patients were initial treatment cases （initial treatment group） while 264 patients were retreatment cases （re-treatment group）. The DST was performed by absolute concentration method for 11 anti-TB drugs. The results showed that the overall drug resistant rate was 50. 70% （253/499） ; the overall drug resistant rate in the initial treatment group （29.79%, 70/235） was statistically significant lower than that in the re-treatment group （69.32%, 183/264） （x2 =79.32, P〈0.01）. The mono-drug-resistant rate in 499 MTB strains was 14. 83% （74/499）; this rate in the initial treatment group and the re-treatment group was 14.04%0 （33/235） and 15.53% （41/264） respectively, there was no statistically significant difference between the two groups （X2 =0.22, P=0. 641）. The poly-drug-resistant rate in 499 MTB strains was 12.63% （63/499） ; this rate in the initial treatment group （2. 98%, 7/235） was statistically significant lower than that in the re-treatment group （21.21% , 56/264） （x2=37.47, P〈0.01）. The multidrug-resistant （MDR） rate in 499 MTB strains was 23.25%/00 （116/499）; the MDR rate in the initial treatment group and the re-treatment group was 12. 77% （30/235） and 32. 58% （86/264） respectively, the former was statistically significant lower than the latter （x2= 27.35, P〈 0.01）. The extensively drug-resistant （XDR） rate in 499 MTB strains was 3.01% （15/499）; the XDR rate in the initial treatment group and the re-treatment group was 0.85% （2/235）
作者
奚莹
石莲
XI Ying;SHI Lian.(Eighth Tuberculosis Ward of Shenyang Chest Hospital, Shenyang Tenth People＇s Hospital, Shenyang 110044, China)
出处
《中国防痨杂志》
CAS
2018年第6期659-662,共4页
Chinese Journal of Antituberculosis
关键词
结核
肺
糖尿病
共病现象
结核
抗多种药物性
数据说明
统计
Tuberculosis
pulmonary
Diabetes mellitus
Comorbidity
Tuberculosis
multidrug-resisrant
Data interpretation
statistical
